tiprankstipranks
Trending News
More News >

Biomea Fusion price target lowered to $18 from $40 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Biomea Fusion (BMEA) to $18 from $40 and keeps a Buy rating on the shares following the Q1 report. The firm removed removing type 1 diabetes from its projections and purged out the projected launch years for icovamenib in type 2 to 2031 from 2029.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue